×

Rapid establishment and/or termination of substantial steady-state drug delivery

  • US 10,231,923 B2
  • Filed: 08/22/2016
  • Issued: 03/19/2019
  • Est. Priority Date: 09/28/2009
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating type 2 diabetes mellitus in a human subject, the method comprising:

  • implanting in the human subject at least one osmotic delivery device comprising an incretin mimetic to provide continuous administration of the incretin mimetic from the at least one osmotic delivery device, wherein(i) continuous administration comprises a first continuous administration period of the incretin mimetic at a first mcg/day dose, followed by a second continuous administration period of the incretin mimetic at a second mcg/day dose, wherein the second mcg/day dose is greater than the first mcg/day dose,(ii) substantial steady-state delivery of the incretin mimetic at a therapeutic concentration is achieved within about 5 days after each implantation of an osmotic delivery device,(iii) substantial steady-state delivery of the incretin mimetic is continuous for at least about 3 months,(iv) the first mcg/day dose followed by the second mcg/day dose is about 20 mcg/day followed by about 60 mcg/day, and(v) the osmotic delivery device comprises a cylindrical reservoir that is capped at one end by a controlled-rate, semi-permeable membrane and capped at the other end by a diffusion moderator.

View all claims
  • 5 Assignments
Timeline View
Assignment View
    ×
    ×